Assessment cycle 2026 Q3 — page 14
Documents ratified in the 2026 Q3 assessment cycle, which ran from 1 July 2026 to 30 September 2026 and was ratified on 18 September 2026.
Documents ratified
-
Submitted-evidence contributor, biostatistics. Hospital microbiology and endotoxin testing service
30 Jul 2026 -
Comment-period correspondent, pharmacy practice. Health-technology assessment agency
30 Jul 2026 -
External reviewer, public health. University department of public health
30 Jul 2026 -
Comment-period correspondent, pharmaceutics. Academic mass-spectrometry core facility
30 Jul 2026 -
External reviewer, patient and public involvement. Sleep and respiratory medicine service
30 Jul 2026 -
External reviewer, biostatistics. National pharmacovigilance centre
30 Jul 2026 -
Comment-period correspondent, hepatology. ISO/IEC 17025-accredited contract testing laboratory
30 Jul 2026 -
External reviewer, public health. University department of medicinal chemistry
30 Jul 2026 -
Submitted-evidence contributor, health-technology assessment. University teaching hospital, department of endocrinology
30 Jul 2026 -
Comment-period correspondent, peptide chemistry. Independent analytical consultancy
30 Jul 2026 -
Submitted-evidence contributor, clinical pharmacology. ISO/IEC 17025-accredited contract testing laboratory
30 Jul 2026 -
Comment-period correspondent, medicines information. Academic peptide-chemistry group
30 Jul 2026 -
Comment-period correspondent, endocrinology. Health-technology assessment agency
30 Jul 2026 -
Submitted-evidence contributor, toxicology. Independent analytical consultancy
30 Jul 2026 -
External reviewer, hepatology. Academic sports-medicine and anti-doping laboratory
30 Jul 2026 -
Comment-period correspondent, pharmacy practice. University teaching hospital, department of endocrinology
30 Jul 2026 -
Submitted-evidence contributor, regulatory science. Academic peptide-chemistry group
30 Jul 2026 -
Specialist adviser, clinical biochemistry. ISO/IEC 17025-accredited contract testing laboratory
30 Jul 2026 -
Comment-period correspondent, toxicology. National medicines information service
30 Jul 2026 -
Submitted-evidence contributor, mass spectrometry. Regional hospital pharmacy department
30 Jul 2026 -
External reviewer, nephrology. University department of public health
30 Jul 2026 -
External reviewer, clinical pharmacology. Public-sector clinical trials unit
30 Jul 2026 -
External reviewer, cardiovascular outcomes. Independent analytical consultancy
30 Jul 2026 -
External reviewer, paediatric endocrinology. Independent evidence-synthesis consultancy
30 Jul 2026 -
Comment-period correspondent, public health. Metabolic medicine service, tertiary centre
30 Jul 2026 -
Comment-period correspondent, evidence synthesis. Community pharmacy practice, doctoral candidate
30 Jul 2026 -
Specialist adviser, endocrinology. University department of pharmacy practice
30 Jul 2026 -
External reviewer, cardiovascular outcomes. Sleep and respiratory medicine service
30 Jul 2026 -
Comment-period correspondent, pharmaceutics. Academic mass-spectrometry core facility
30 Jul 2026 -
External reviewer, public health. Metabolic medicine service, tertiary centre
30 Jul 2026 -
Comment-period correspondent, paediatric endocrinology. University department of pharmacy practice
30 Jul 2026 -
Submitted-evidence contributor, microbiological quality. National medicines information service
30 Jul 2026 -
External reviewer, clinical biochemistry. Public-sector clinical trials unit
30 Jul 2026 -
Peptides, SARMs, injectable oils and raw materials.
29 Aug 2026
page 14 of 14